Alimera Sciences (ALIM -14%) takes a hit today after the UK's National Institute for Health and Clinical Excellence issued final draft guidance indicating that Iluvien is not recommended for the treatment of chronic diabetic macular edema. The agency noted the drug was insufficiently responsive to available therapies, and that that cost-effectiveness thresholds weren't met.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs